RCS - GenIP PLC - Technology Park Alliance

GenipAnnouncement

15/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO3763Da&default-theme=true

RNS Number : 3763D  GenIP PLC  15 October 2025

 

 

 

15 October 2025

 

GenIP Plc

("GenIP" or the "Company")

 

Technology Park Alliance

 

GenIP Plc, a technology consultancy providing Generative Artificial
Intelligence (GenAI) services to help research organisations and corporations
commercialise their innovations, is pleased to announce a new collaboration
with Pelotas Science Park (Parque Tecnológico de Pelotas) in Brazil, marking
our first engagement with a technology park.

 

Pelotas Science Park serves as an innovation hub integrating the "quadruple
helix": government, academia, industry, and civil society, and brings together
incubators, coworking space, a regional startup network (Candy Valley), 63
resident and non-resident enterprises, and 23 partner institutions.

 

Under this partnership, GenIP will provide its suite of services to many
of the park's tenant companies and incubated startups, guiding their
decision-making process on which technologies are most viable for investment
and commercialisation.

 

This agreement represents GenIP's efforts to lay the foundations for future
growth through strategic alliances and partnerships, and aligns with the
Company's strategic goal to diversify its client base beyond research
organisations in order to increase the proportion of corporate clients to 45%
of total clients.

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"Our collaboration with Pelotas Science Park represents an important milestone
for GenIP as we expand our reach beyond universities to support entire
innovation ecosystems. Science parks play a vital role in Technology Transfer
by connecting researchers, startups, and industry partners, and we're proud
to provide the analytical foundation that helps their tenant companies
identify commercially viable technologies and attract investment. This
partnership reflects our broader strategy to deepen engagement with industry
and startup communities,  bringing us closer to our goal of achieving 45%
industry participation."

 

Vinicius Farías Campos, President at Pelotas Technology Park, commented:

 

"Through its Health and Biotechnology Innovation Hub, the Pelotas Technology
Park is proud to collaborate with GenIP in applying AI-driven methodologies
for technology assessment and valorization. This partnership accelerates the
translation of scientific research into real-world applications, strengthening
Southern Brazil's innovation ecosystem in health and biotechnology."

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                          Via Redchurch Communications

 Melissa Cruz, CEO

 AlbR Capital Limited (Broker)                                      Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                      cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                        Jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                            genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI
and innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies                                                         investment, and IP strategy
 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●     Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach
to corporates, VCs, and research institutions, supported by strategic
marketing and digital engagement.

●     Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFSFALEISELS



            Copyright 2019 Regulatory News Service, all rights reserved